Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Daridorexant on Midazolam and Warfarin PK/PD
NCT05480488Phase 1Completed
- Sponsor
- Idorsia
- Start
- Aug 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daridorexant in Insomnia, sponsored by Idorsia. Primary endpoints: Maximum concentration (Cmax) of midazolam and 1-OH midazolam, Cmax of S-warfarin and 6 more. Started Aug 2022; status: completed.
02
Drugs
daridorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT05480488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05480488.